Lexeo Therapeutics, Inc. Common Stock (LXEO) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-69.1%

$0.95

vs $3.06 price

Levered DCF

$1.03

After debt service

Piotroski score

1 / 9

Weak

Altman Z-score

5.08

Safe zone

Rating

B-

Overall 2 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
P/E	-5.34×	-2.13×	-5.39×	-4.26×	-5×	-50.25×
P/B	2.16×	1.79×	3.15×	-2.24×	-4.55×	-45.69×
P/S	0×	0×	0×	386.78×	152.66×	487.88×
EV / EBITDA	-4.89×	-1.91×	-3.85×	-3.26×	-2.31×	-48.73×
Gross margin	0.0%	0.0%	0.0%	100.0%	100.0%	100.0%
Operating margin	0.0%	0.0%	0.0%	-9252.1%	-3055.9%	-884.9%
Net margin	0.0%	0.0%	0.0%	-9063.8%	-3055.0%	-993.8%
Current ratio	11.21×	5.52×	7.21×	5.58×	18.35×	42.15×
Debt / equity	0.03×	0.08×	0.1×	-0.12×	0×	0×
Interest coverage	-530.37×	-927.77×	-334.21×	-664.93×	0×	-31.18×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Return on equity	-40.5%	-84.2%	-58.5%	52.5%	91.0%	93.1%
Return on invested capital	-42.9%	-83.4%	-54.7%	-67.4%	-39.1%	-16.0%
Return on assets	-37.2%	-66.9%	-47.5%	-61.1%	-37.0%	-17.5%
Free cash flow yield	-18.6%	-39.0%	-16.7%	-21.9%	-17.5%	-1.2%
Earnings yield	-18.8%	-47.0%	-18.6%	-23.4%	-20.0%	-2.0%
Enterprise value	$477.6M	$184.1M	$247.8M	$189.1M	$117.1M	$223.6M
Net debt / EBITDA	0.56×	0.26×	1.71×	1.1×	2.68×	6.4×
Cash conversion cycle (days)	0	0	0	0	0	0